News

Weight-Loss Drugs Aren’t Really About Weight
Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...
Novo Nordisk announces CEO transition as share price slips
In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...
Eli Lilly pulls ahead of Novo in obesity drug gold rush as new players crowd in
Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...
Novo Nordisk, U.S. biotech company team up to create obesity pills
Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...
Novo Nordisk CEO's Surprise Exit After Setbacks in Weight-Loss Market
"The Novo Nordisk Foundation is increasing its influence and has appointed its chairman, Lars Rebien Sørensen, as an observer ...
Indianapolis Business Journal2d
Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
Zepbound beats Wegovy for weight loss in trial of blockbuster drugs
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
Wellness companies eager to avoid WeightWatchers’ fate embrace weight-loss drugs
Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...